stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Book value per share
Replimune Group, Inc.'s book value per share at the end of fiscal 2026 was 1.8×, down 65.3% from 5.2× in fiscal 2025. At the end of the quarter to 30 September 2026 it was 1.9×. Over the past ten years it has ranged from −5.6× (fiscal 2018) to 10.8× (fiscal 2021); the current reading is higher than 30% of that period. Replimune Group, Inc. ranks 282nd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2026 | 1.8× | (65.31%) |
| FY2025 | 5.2× | (8.25%) |
| FY2024 | 5.6× | (41.02%) |
| FY2023 | 9.5× | 21.11% |
| FY2022 | 7.9× | (26.96%) |
| FY2021 | 10.8× | 101.10% |
| FY2020 | 5.4× | (9.77%) |
| FY2019 | 5.9× | — |
| FY2018 | −5.6× | — |
| FY2017 | −2.3× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 1.9× | 78.51% |
| Jun 2026 | 1.1× | (39.08%) |
| Mar 2026 | 1.8× | (21.60%) |
| Dec 2025 | 2.3× | (20.29%) |
| 35 more quarters | Free account |
Against its own ten years
Low −5.6×
High 10.8×
Ten-year median
5.5×
Current reading's percentile
30
Book value per share against peers
| Company | Book value per share |
|---|---|
| VERA Vera Therapeutics, Inc. compare | 5.7× |
| VIR Vir Biotechnology, Inc. compare | 5.3× |
| AUPH Aurinia Pharmaceuticals Inc compare | 4.9× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 4.2× |
| IMNM Immunome, Inc. compare | 4.0× |
| ZYME Zymeworks Inc. compare | 3.6× |
| REPL Replimune Group, Inc. | 1.9× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 1.7× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))